Stockreport

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

BioAge Labs, Inc.  (BIOA) 
Last bioage labs, inc. earnings: 8/3 07:00 am Check Earnings Report
US:NYSE Investor Relations: investor.bio-amber.com
PDF 120 mg and newly announced 60 mg once-daily doses each achieved =85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was [Read more]